Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.45 |
| ▸ | SQLE | Q14534 | 7/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42402 | 0.95 | KMT2A (0.42) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL42401 | 0.95 | KMT2A (0.42) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7070996 | 0.82 | SQLE (0.36) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL19274201 | 0.81 | KMT2A (0.76) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL27099651 | 0.81 | KMT2A (0.76) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL5576405 | 0.81 | KMT2A (0.76) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7347532 | 0.80 | KMT2A (0.48) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7347537 | 0.80 | KMT2A (0.48) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7323717 | 0.80 | KMT2A (0.48) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL2524497 | 0.80 | KMT2A (0.48) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039647-B2 | 2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20090306408-A1 | 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306408-A1 | 2-Amino-Bicyclo (3.1.0) Hexane-2,6-Dicarboxylic Ester Derivative | GRIK4, GRIN2D, GRIN2C | KMT2A 1954/4885MAPT 1364/4885MEN1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.